הודעה בפורום

:-) הקורי הלקה	:םש
hakalayeruka@yahoo.com	:ינורטקלא ראוד
22:06 15/11/03	:ךיראת
Relieve symptoms - תשרט	:אשונ

:העדוה

050.481888 -ירוא םע רשק ורצ ,לארשיב ןיינעה לע םיטרפ
.HakalaYeruka@yahoo.com לאודב וא

shows Cannabis reduces symptoms of multiple sclerosis.
Science: large British study

study of the use of cannabis and THC (dronabinol) to
The biggest
symptoms of multiple sclerosis produced mixed results but
relieve
to warrant licensing the treatment for the illness.
doctors said there is enough evidence

there was no objective evidence that cannabis relieved
Although
or muscle stiffness, caused by the disease, patients
spasticity,
improvements in pain relief and rigidity. Mobility was
reported
improved as well.

with stable MS and muscle spasticity received either
657 patients
a capsulated cannabis extract, THC or a placebo. Cannabis
contained 2.5 mg THC and 1.25 mg cannabidiol (CBD).
capsules
lasted 15 weeks. It started with a 5-week dose titration
The trial
During this period, patients were asked to increase their
phase:
dose by one capsule twice daily at weekly intervals up to a
maximum daily dose of 10-25 mg THC (depending on body
If side effects developed, patients were advised not to
weight).
increase the dose.

The medication was generally well tolerated. There was no
evidence, that spasticity measured by the spasticity scale
objective
according to Ashworth was improved. However, there was a
towards a small improvement with cannabis and THC, with
trend
reduction in total Ashworth score for cannabis of 0.32 and
a mean
THC of 0.42 compared to placebo. There was evidence of a
for
treatment effect on some subjective symptoms. 61 and 60
respectively, of patients receiving cannabis extract or
percent,
reported an improvement in spasticity, compared to only 46
THC
with placebo. Corresponding figures for pain were 42, 35
percent
and 26 percent respectively. There was also evidence of an
of walking ability with cannabis and THC for mobile
improvement
patients.

a range of positives and a range of negatives. Overall, I
“There is
there is enough evidence to take this forward with the
think
and regulatory authorities,” Dr. John Zajicek, who
licensing
headed the study, told Reuters. He said the research raises
about what's more important: a doctor's measurements
questions
or the patient's perspective.

there's a conflict, it's what the patient feels which is
"I think if
so I think it's quite encouraging," Dr. Roger Pertwee, a
important,
of neuropharmacology at University of Aberdeen, who
professor
was not connected with the study, told Associated Press.

for the mixed results could be the muscle test,
One explanation
the Ashworth scale, is not sensitive enough to detect
called
that are meaningful to patients. "It is very far removed
changes
everyday life. Moving someone's leg up and down when he
from
on a table doesn't necessarily translate very well into
is lying flat
happens when they get up and try to walk around or do the
what
housework or whatever," Dr. Alan Thompson, professor of
neurology from London, said.

Nunn A, Thompson A, on behalf of the UK MS Research Group.
Sources: Zajicek J, Fox P, Sanders H, Wright D, Vickery J,
related to multiple sclerosis (CAMS study): multicentre
Cannabinoids for treatment of spasticity and other symptoms
of 7 November 2003, Associated Press of 6 November 2003)
trial. Lancet 2003; 362(9385): 1517-1526. Reuters
randomised placebo-controlled

רקחמל רושיק

67771 ,ופי ביבא לת ,16 לדגמו המוח :תבותכ | (ר"ע) הצופנ תשרטל תילארשיה הדוגאה
15:00 - 09:00 :הלבק תועש | agudaims@netvision.net.il :ינורטקלא ראוד | 03-5377004 :סקפ | 03-5377002 :ןופלט